Emepepimut-S for non-small cell lung cancer

Bibliography

• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45
   PubMed Web of Science ®Google Scholar
• Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970;13:1-27
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
   PubMed Web of Science ®Google Scholar
• Bradbury PA, Shepherd FA. Immunotherapy for lung cancer. J Thorac Oncol 2008;3(6 Suppl 2):S164-70
   PubMed Web of Science ®Google Scholar
• Ferlay J, Shin HR, Bray F, Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest 2009;136:260-71
   PubMed Web of Science ®Google Scholar
• Van Hemelrijck MJ, Kabir Z, Connolly GN. Trends in lung cancer death rates in Belgium and The Netherlands: a systematic analysis of temporal patterns. J Community Health 2009;34:188-94
   PubMed Web of Science ®Google Scholar
• Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur J Cancer 2004;40:96-125
   PubMed Web of Science ®Google Scholar
• Jemal A, Thun MJ, Ries LA, Annual report to the nation on the status of cancer, 1975 – 2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100:1672-94
   PubMed Web of Science ®Google Scholar
• Souquet PJ, Chauvin F, Boissel JP, Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21
   PubMed Web of Science ®Google Scholar
• Navaratnam S, Kliewer EV, Butler J, Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 2010;70:110-15
   PubMed Web of Science ®Google Scholar
• Ho SB, Niehans GA, Lyftogt C, Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res 1993;53:641-51
   PubMed Web of Science ®Google Scholar
• Awaya H, Takeshima Y, Yamasaki M, Inai K. Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung. Am J Clin Pathol 2004;121:644-53
   PubMed Web of Science ®Google Scholar
• Rahn JJ, Dabbagh L, Pasdar M, Hugh JC. The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 2001;91:1973-82
   PubMed Web of Science ®Google Scholar
• Ding L, Lalani EN, Reddish M, Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother 1993;36:9-17
   PubMed Web of Science ®Google Scholar
• Baldus SE, Monig SP, Hanisch FG, Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology 2002;40:440-9
   PubMed Web of Science ®Google Scholar
• Kontani K, Taguchi O, Narita T, Modulation of MUC1 mucin as an escape mechanism of breast cancer cells from autologous cytotoxic T-lymphocytes. Br J Cancer 2001;84:1258-64
   PubMed Web of Science ®Google Scholar
• Guddo F, Giatromanolaki A, Koukourakis MI, MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol 1998;51:667-71
   PubMed Web of Science ®Google Scholar
• Nagai S, Takenaka K, Sonobe M, A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. J Thorac Oncol 2006;1:46-51
   PubMed Web of Science ®Google Scholar
• Palmer M, Parker J, Modi S, Phase I study of the BLP25 (MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB/IV non-small-cell lung cancer. Clin Lung Cancer 2001;3:49-57; discussion 58
   PubMedGoogle Scholar
• Gridelli C, Rossi A, Maione P, Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy. Oncologist 2009;14:909-20
   PubMed Web of Science ®Google Scholar
• North SA, Graham K, Bodnar D, Venner P. A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy. J Urol 2006;176:91-5
   PubMed Web of Science ®Google Scholar
• Pochampalli MR, el Bejjani RM, Schroeder JA. MUC1 is a novel regulator of ErbB1 receptor trafficking. Oncogene 2007;26(12):1693-701
   PubMed Web of Science ®Google Scholar
• Hisatsune A, Nakayama H, Kawasaki M, Anti-MUC1 antibody inhibits EGF receptor signaling in cancer cells. Biochem Biophys Res Commun 2011;405:377-81
   Google Scholar
• Sangha R, Butts C. L-BLP25: a peptide vaccine strategy in non small cell lung cancer. Clin Cancer Res 2007;13(15 Pt 2):s4652-4
   PubMed Web of Science ®Google Scholar
• Agrawal B, Krantz MJ, Reddish MA, Longenecker BM. Rapid induction of primary human CD4+ and CD8+ T cell responses against cancer-associated MUC1 peptide epitopes. Int Immunol 1998;10:1907-16
   PubMed Web of Science ®Google Scholar
• Guan HH, Budzynski W, Koganty RR, Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998;9:451-8
   PubMed Web of Science ®Google Scholar
• Ohyanagi F, Horai T, Sekine I, L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study. J Clin Oncol 2010;28(Suppl):abstract e13153
   Google Scholar
• Butts C, Murray N, Maksymiuk A, Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81
   PubMed Web of Science ®Google Scholar
• Bass KK, Mastrangelo MJ. Immunopotentiation with low-dose cyclophosphamide in the active specific immunotherapy of cancer. Cancer Immunol Immunother 1998;47:1-12
   PubMed Web of Science ®Google Scholar
• MacLean GD, Miles DW, Rubens RD, Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 1996;19:309-16
   PubMed Web of Science ®Google Scholar
• Butts C, Maksymiuk A, Goss G, A multi-centre phase IIB randomized controlled study of BLP25liposome vaccine (L-BLP25 or Stimuvax) for active specific immunotherapy of non-small cell lung cancer (NSCLC): updated survival analysis [abstract B1-01]. J Thorac Oncol 2007;2:S322-3
   Google Scholar
• Butts C, Murray RN, Smith CJ, A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-Small-cell lung cancer. Clin Lung Cancer 2010;11:391-5
   PubMedGoogle Scholar
• Merck KGaA. Study of EMD531444 in subjects with stage III unresectable Non-small Cell Lung Cancer (NSCLC) following primary chemoradiotherapy. 2011. Clinicaltrials.gov NCT00960115 Available from: http://clinicaltrials.gov/show/NCT00960115.htm
   Google Scholar
• Eastern Cooperative Oncology Group. BLP25 Liposome vaccine and bevacizumab after chemotherapy and radiation therapy in treating patients with newly diagnosed stage IIIA or stage IIIB Non-small cell lung cancer that cannot be removed by surgery. 2011. Clinicaltrials.gov NCT00828009 Available from: http://clinicaltrials.gov/show/NCT00828009.htm
   Google Scholar
• Merck KGaA. Cancer vaccine study for stage III, unresectable, Non-small cell lung cancer (NSCLC) in the asian population (INSPIRE). 2011. Clinicaltrials.gov NCT01015443 Available from: http://clinicaltrials.gov/show/NCT01015443.htm
   Google Scholar
• EMD Serono. Cancer vaccine study for unresectable stage III Non-small cell lung cancer. 2011. Clinicaltrials.gov NCT00409188 Available from: http://clinicaltrials.gov/show/NCT00409188.htm
   Google Scholar
• Butts C, Anderson H, Maksymiuk A, Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(15S):abstract 3055
   Google Scholar
• Soulieres D, Smith C, Ellis PM, A multi-centre, open-label study to assess the safety of Stimuvax (BLP25 liposome vaccine or L-BLP25) in non-small cell lung cancer (NSCLC) patients (pts) with unresectable stage III disease. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007;25(18S):abstract 3075
   Google Scholar
• Merck Serono Resumes Stimuvax Clinical Program in Lung Cancer. Darmstadt, Germany: Merck-Serono, 2010. Available from: http://www.merck.de/en/media/extNewsDetail.html?newsId=0BDEF079C946D24FC1257744005B84C0&newsType=1 [Last accessed 27 May 2011]
   Google Scholar